ASRS LIVE: Anatomic/functional outcomes of various surgical approaches for progressive RDs Secondary to retinoschisisJuly 16th 2022
Speaking at the American Society of Retina Specialists 2022 annual meeting at the Jacob K. Javits Convention Center in New York, J. Fernando Arevalo, MD, PhD, The Edmund F. and Virginia B. Ball Professor of Ophthalmology, chairman of ophthalmology at Johns Hopkins Bayview Medical Center, Wilmer Eye Institute, Johns Hopkins University, Baltimore, outlined his investigation of the anatomic and functional outcomes of pars plana vitrectomy, scleral buckle, or a combination of the 2, and suggested that the combination approach may need further consideration.
ASRS LIVE: TRUCKEE Study shows real-world safety and efficacy of faricimab for neovascular AMDJuly 16th 2022
Speaking at the American Society of Retina Specialists 2022 annual meeting in New York, Carl Danzig, MD, detailed how treatment with faricimab in patients with neovascular AMD resulted in improvements in visual acuity, central subfield thickness and pigment epithelial detachments.
ASRS LIVE: Tools developed to identify risk of vision loss to diabetic retinopathyJuly 15th 2022
During a presentation at the American Society of Retina Specialists 2022 annual meeting in New York, Bobeck S. Modjtahedi, MD, presented results of a study that examined the accuracy of tools for predicting the risk of vision-threatening diabetic retinopathy.
ASRS Live: Diabetic therapy metformin may have protective effect against AMDJuly 15th 2022
In a presentation at the American Society of Retina Specialists, Dimitra Skondra, MD, PhD, points out that the low-to-moderate doses of metformin carried the greatest potential benefit in a retrospective case-control study.
ASRS LIVE: Pearls for tackling pediatric retinal detachment surgery in USJuly 14th 2022
In a presentation at the American Society of Retina Specialists 2022 annual meeting at the Jacob K. Javits Convention Center in New York, Yoshihiro Yonekawa, MD, detailed that primary scleral buckling achieved the best visual acuity, and pointed out that rhegmatogenous detachments increased with age.
Two-year data confirms faricimab improves vision for patients diagnosed with wet-AMDJuly 14th 2022
In the TENAYA and LUCERNE studies, more than 60% of faricimab patients could be treated every 4 months at 2 years, an increase from 45% at year 1. Study results are being presented at the American Society of Retina Specialists 2022 annual meeting in New York.
Measuring levels of proteins in eye fluid may accurately predict need for lifelong macular degeneration therapyJuly 7th 2022
A team of investigators form Johns Hopkins Medicine say they’ve discovered that levels of a specific protein appears to help accurately predict whether people with the wet form of age-related macular degeneration may need lifelong, frequent eye injections to preserve vision or if they can be safely weaned off the treatments.
Novel therapy using thermogel prevents retinal scarringJuly 5th 2022
A team of investigators at the Agency for Science, Technology and Research in Singapore have developed a bio-functional thermogel, a type of synthetic polymer, to prevent retinal scarring caused by failed retinal detachment repair surgery.
Analyzing real-world registry study of YUTIQ for chronic non-infectious posterior uveitisOctober 12th 2021
Ankur Shah, MD, discusses key highlights of his presentation titled "YUTIQ CALM: a real-world registry study of the fluocinolone acetonide intravitreal implant 0.18 mg in chronic non-infectious posterior uveitis," during ASRS 2021.
Looking to the future of retina innovationsAugust 16th 2020
Retina specialists Caesar Luo, MD, of Bay Area Retina Associates (Walnut Creek, CA) and S.K. Steven Houston III, MD, of Florida Retina Institute, share their outlooks on retina innovation in the "year of the eye" amid a global pandemic.
Evaluating 3-year recurrence rate in non-infectious posterior segment uveitis post-FAiAugust 11th 2020
Dilraj Grewal, MD, speaks on his presentation "Evaluating the True 3-Year Recurrence Rate in Non-infectious Posterior Segment Uveitis Following an Injectable Fluocinolone Acetonide Insert," during ASRS 2020.
Impact of baseline OCT on response to risuteganib for treatment of intermediate AMD (ASRS 2020)August 4th 2020
Justis P. Ehlers, MD, speaks on the key findings and take-aways from his presentation "Impact of baseline OCT characteristics on response to risuteganib for the treatment of intermediate age-related macular degeneration (AMD)."
Dexamethasone intracameral drug-delivery suspension in vitreoretinal surgery inflammation (ASRS 2020)August 3rd 2020
Daniel F. Kiernan, MD, FACS, speaks on the key findings and take-aways of his presentation "Dexamethasone intracameral drug-delivery suspension for inflammation associated with vitreoretinal surgery."
How one surgeon is integrating recent retina advances in COVID-19 (ASRS 2020)August 2nd 2020
S.K. Steven Houston III, MD, discusses retina innovations in use in his practice, including the NGENUITY 1.4 upgrade from Alcon, and adapting to ever-changing operating room spacing and set-up in the COVID-19 environment
AsclepiX lead candidate holds potential for wet AMD, DME, RVO (ASRS 2020)July 31st 2020
Theresa Heah, MD, provides an update on AsclepiX’s AXT107, which is derived from a cryptic peptide within collagen IV that works by activating naturally existing, homeostatic mechanisms of angiogenesis.